Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes.

Smith KS, Rudolph U.

Neuropharmacology. 2012 Jan;62(1):54-62. doi: 10.1016/j.neuropharm.2011.07.026. Epub 2011 Jul 27. Review.

2.

Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior.

Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF.

Neuropsychopharmacology. 2004 Jun;29(6):1050-62.

3.

The GABA system in anxiety and depression and its therapeutic potential.

Möhler H.

Neuropharmacology. 2012 Jan;62(1):42-53. doi: 10.1016/j.neuropharm.2011.08.040. Epub 2011 Sep 1. Review.

PMID:
21889518
4.

Somatostatin receptor subtype 4 activation is involved in anxiety and depression-like behavior in mouse models.

Scheich B, Gaszner B, Kormos V, László K, Ádori C, Borbély É, Hajna Z, Tékus V, Bölcskei K, Ábrahám I, Pintér E, Szolcsányi J, Helyes Z.

Neuropharmacology. 2016 Feb;101:204-15. doi: 10.1016/j.neuropharm.2015.09.021. Epub 2015 Sep 18.

PMID:
26387439
5.

α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.

Engin E, Liu J, Rudolph U.

Pharmacol Ther. 2012 Nov;136(2):142-52. doi: 10.1016/j.pharmthera.2012.08.006. Epub 2012 Aug 18. Review.

6.

Effects of GABAB receptor ligands in animal tests of depression and anxiety.

Frankowska M, Filip M, Przegaliński E.

Pharmacol Rep. 2007 Nov-Dec;59(6):645-55.

7.

Designing new treatments for depression and anxiety.

Chen Z, Yang J, Tobak A.

IDrugs. 2008 Mar;11(3):189-97. Review.

PMID:
18311656
9.

GABAB receptors and depression. Current status.

Cryan JF, Slattery DA.

Adv Pharmacol. 2010;58:427-51. doi: 10.1016/S1054-3589(10)58016-5. Review.

PMID:
20655491
10.

New insights into BDNF function in depression and anxiety.

Martinowich K, Manji H, Lu B.

Nat Neurosci. 2007 Sep;10(9):1089-93. Review.

PMID:
17726474
11.

Depression & Anxiety-SMi Conference. Shining light into dark corners. 12-13 May 2003, London, UK.

Durrance A.

IDrugs. 2003 Jul;6(7):664-7. No abstract available.

PMID:
12908452
12.

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.

Hodgson RA, Mullins D, Lu SX, Guzzi M, Zhang X, Bleickardt CJ, Scott JD, Miller MW, Stamford AW, Parker EM, Varty GB.

Eur J Pharmacol. 2014 May 5;730:157-63. doi: 10.1016/j.ejphar.2014.02.027. Epub 2014 Mar 4.

PMID:
24602808
13.

[The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].

Ströhle A.

Nervenarzt. 2003 Mar;74(3):279-91; quiz 292. German.

PMID:
12627245
14.

Pharmacological reversal of cognitive bias in the chick anxiety-depression model.

Hymel KA, Sufka KJ.

Neuropharmacology. 2012 Jan;62(1):161-6. doi: 10.1016/j.neuropharm.2011.06.009. Epub 2011 Jun 23.

PMID:
21722654
15.

Drug interactions at GABA(A) receptors.

Korpi ER, Gründer G, Lüddens H.

Prog Neurobiol. 2002 Jun;67(2):113-59. Review.

PMID:
12126658
16.

Reduced anxiety and depression-like behavior in synaptotagmin IV (-/-) mice.

Ferguson GD, Herschman HR, Storm DR.

Neuropharmacology. 2004 Sep;47(4):604-11.

PMID:
15380377
17.

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.

Griebel G, Stemmelin J, Gal CS, Soubrié P.

Curr Pharm Des. 2005;11(12):1549-59. Review.

PMID:
15892661
18.

Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test.

Rezvanfard M, Zarrindast MR, Bina P.

Pharmacology. 2009;84(6):356-66. doi: 10.1159/000256666. Epub 2009 Nov 11.

PMID:
19907194
20.

Functional mapping of GABA A receptor subtypes in the amygdala.

Marowsky A, Fritschy JM, Vogt KE.

Eur J Neurosci. 2004 Sep;20(5):1281-9.

PMID:
15341600

Supplemental Content

Support Center